In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019

por Klippel, Zandra, Kimball, Amy, Tekle, Christina
Publicado en Blood Cancer J (2019)

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

por Li, Yanli, Klippel, Zandra, Shih, Xiaolong, Wang, Hong, Reiner, Maureen, Page, John H.
Publicado en Cancer Chemother Pharmacol (2016)

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

por Li, Yanli, Family, Leila, Chen, Lie H., Page, John H., Klippel, Zandra, Xu, Lanfang, Chao, Chun R.
Publicado en Cancer Med (2018)

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

por Klippel, Zandra K., Chou, Jeffrey, Towlerton, Andrea M., Voong, Lilien N., Robbins, Paul, Bensinger, William I., Warren, Edus H.
Publicado 2014

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer

por Nordstrom, Beth L., Simeone, Jason C., Malley, Karen G., Fraeman, Kathy H., Klippel, Zandra, Durst, Mark, Page, John H., Xu, Hairong
Publicado en Front Oncol (2016)

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

por Dale, David C., Crawford, Jeffrey, Klippel, Zandra, Reiner, Maureen, Osslund, Timothy, Fan, Ellen, Morrow, Phuong Khanh, Allcott, Kim, Lyman, Gary H.
Publicado en Support Care Cancer (2017)

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous...

por Cowan, Andrew J., Klippel, Zandra K., Stevenson, Philip A., Hyun, Teresa S., Tuazon, Sherilyn, Becker, Pamela S., Green, Damian J., Holmberg, Leona A., Coffey, David G., Gopal, Ajay K., Libby, Edward N.
Publicado en Amyloid (2016)

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

por Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Publicado en Cancer Med (2020)

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

por Facon, Thierry, Niesvizky, Ruben, Mateos, Maria-Victoria, Siegel, David, Rosenbaum, Cara, Bringhen, Sara, Weisel, Katja, Ho, P. Joy, Ludwig, Heinz, Kumar, Shaji, Wang, Kenneth, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra, Mezzi, Khalid, Goldrick, Amanda, Tekle, Christina, Dimopoulos, Meletios A.
Publicado en Blood Adv (2020)